Ursula Ebinger

746 total citations
12 papers, 543 citations indexed

About

Ursula Ebinger is a scholar working on Urology, Rheumatology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ursula Ebinger has authored 12 papers receiving a total of 543 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Urology, 5 papers in Rheumatology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ursula Ebinger's work include Urinary Bladder and Prostate Research (7 papers), Pelvic floor disorders treatments (5 papers) and Urinary Tract Infections Management (4 papers). Ursula Ebinger is often cited by papers focused on Urinary Bladder and Prostate Research (7 papers), Pelvic floor disorders treatments (5 papers) and Urinary Tract Infections Management (4 papers). Ursula Ebinger collaborates with scholars based in United States, Switzerland and United Kingdom. Ursula Ebinger's co-authors include Gary G. Kay, Ludmyla Rekeda, Thomas H. Crook, Michael Steel, Christopher R. Chapple, Catherine E. DuBeau, José M. Brum, Brian Olshansky, Patricia Koochaki and Norman R. Zinner and has published in prestigious journals such as Circulation, European Urology and Urology.

In The Last Decade

Ursula Ebinger

12 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ursula Ebinger United States 9 422 368 251 63 53 12 543
Daniela Marschall‐Kehrel Germany 13 570 1.4× 464 1.3× 274 1.1× 95 1.5× 42 0.8× 27 697
P. Van Kerrebroeck Netherlands 8 563 1.3× 312 0.8× 167 0.7× 154 2.4× 17 0.3× 25 643
J J Wyndaele Belgium 11 383 0.9× 206 0.6× 126 0.5× 79 1.3× 8 0.2× 17 481
Joseph T. Wang United States 16 699 1.7× 562 1.5× 329 1.3× 128 2.0× 38 0.7× 22 753
Gloria M. Harrison Canada 10 320 0.8× 300 0.8× 154 0.6× 51 0.8× 13 0.2× 12 412
Tove Holm‐Larsen Denmark 11 218 0.5× 118 0.3× 68 0.3× 59 0.9× 13 0.2× 30 339
Karen Irvine‐Bird Canada 9 297 0.7× 207 0.6× 164 0.7× 44 0.7× 12 0.2× 10 400
Asplund Sweden 7 256 0.6× 122 0.3× 93 0.4× 74 1.2× 2 0.0× 7 397
David Holmes United Kingdom 8 200 0.5× 273 0.7× 87 0.3× 148 2.3× 9 0.2× 19 380
O. A. Adekanmi United Kingdom 11 107 0.3× 129 0.4× 53 0.2× 86 1.4× 4 0.1× 16 345

Countries citing papers authored by Ursula Ebinger

Since Specialization
Citations

This map shows the geographic impact of Ursula Ebinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursula Ebinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursula Ebinger more than expected).

Fields of papers citing papers by Ursula Ebinger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ursula Ebinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursula Ebinger. The network helps show where Ursula Ebinger may publish in the future.

Co-authorship network of co-authors of Ursula Ebinger

This figure shows the co-authorship network connecting the top 25 collaborators of Ursula Ebinger. A scholar is included among the top collaborators of Ursula Ebinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ursula Ebinger. Ursula Ebinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Sato, Naoki, Wataru Takahashi, Atsushi Hirayama, et al.. (2015). LATE BREAKING CLINICAL TRIAL (JCS 2015) : Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Circulation. 79(6). 1237–1247. 10 indexed citations
2.
Sato, Naoki, Wataru Takahashi, Atsushi Hirayama, et al.. (2015). Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure. Circulation Journal. 79(6). 1237–1247. 18 indexed citations
3.
Kay, Gary G. & Ursula Ebinger. (2008). Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. International Journal of Clinical Practice. 62(11). 1792–1800. 99 indexed citations
4.
Chancellor, Michael B., et al.. (2008). A comparison of the efficacy of darifenacin alone vs. darifenacin plus a Behavioural Modification Programme upon the symptoms of overactive bladder. International Journal of Clinical Practice. 62(4). 606–613. 31 indexed citations
5.
Zinner, Norman R., et al.. (2008). Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. International Journal of Clinical Practice. 62(11). 1664–1674. 40 indexed citations
6.
Dwyer, Peter, Con Kelleher, Jay M. Young, et al.. (2008). Long‐term benefits of darifenacin treatment for patient quality of life: Results from a 2‐year extension study. Neurourology and Urodynamics. 27(6). 540–547. 16 indexed citations
7.
Olshansky, Brian, et al.. (2008). Antimuscarinics and Heart Rate: Results from a Randomized, Double-Blind, Placebo-Controlled, 3 Way Crossover Study in Subjects Over Age 50. UroToday International Journal. 1(0). 1 indexed citations
8.
9.
Andersson, Karl‐Erik, Kristijan H. Kahler, & Ursula Ebinger. (2007). Heart Rates in OAB Patients Prior to Initiation of Treatment with Antimuscarinics. Neurourology and Urodynamics. 1 indexed citations
10.
Chapple, Christopher R., et al.. (2007). Darifenacin treatment of patients ≥ 65 years with overactive bladder: results of a randomized, controlled, 12-week trial. Current Medical Research and Opinion. 23(10). 2347–2358. 70 indexed citations
11.
12.
Kay, Gary G., et al.. (2006). Differential Effects of the Antimuscarinic Agents Darifenacin and Oxybutynin ER on Memory in Older Subjects. European Urology. 50(2). 317–326. 208 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniela Marschall‐Kehrel Breakdown of academic impact, for papers by P. Van Kerrebroeck Breakdown of academic impact, for papers by J J Wyndaele Breakdown of academic impact, for papers by Joseph T. Wang Breakdown of academic impact, for papers by Gloria M. Harrison Breakdown of academic impact, for papers by Tove Holm‐Larsen Breakdown of academic impact, for papers by Karen Irvine‐Bird Breakdown of academic impact, for papers by Asplund Breakdown of academic impact, for papers by David Holmes Breakdown of academic impact, for papers by O. A. Adekanmi
Rankless by CCL
2026